Lithium increases expression of p21WAF/Cip1 and survivin in human glioblastoma cells

Cell Biology and Toxicology

Volumn 23, Issue 2, 2007, Pages 83-90

  Karlovic, D ^a   Jakopec, S ^b   Dubravcic, K ^a   Batinic, D ^a   Buljan, D ^a   Osmak, M ^b  

^a KBC Zagreb   (Croatia)

^b RUDER BO KOVI INSTITUTE   (Croatia)

Author keywords

Apoptosis; Glioblastoma cells; Lithium; p21WAF Cip1; Survivin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; LITHIUM CHLORIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROCASPASE 3; PROTEIN BCL 2; SURVIVIN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION; GLIA CELL; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION;

APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; GLIOBLASTOMA; HUMANS; LITHIUM; MICROTUBULE-ASSOCIATED PROTEINS; NEOPLASM PROTEINS; NEUROGLIA;

EID: 33846460869     PISSN: 07422091     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10565-006-0126-9     Document Type: Article

References (34)

1. Altieri DC. Validating survivin as a cancer therapeutic target. Nat Rev Cancer. 2003;3:46-54.
2. Ashe PC, Berry MD. Apoptotic signaling cascades. Prog Neuro-Psychopharmacol Biol Psychiatry. 2003;27:199-214.
3. Chen G, Zeng WZ, Yuan PX, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 1999;72:879-82.
4. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. J Biol Chem. 1999;274:6039-42.
5. Corson TW, Woo KK, Li PP, Warsh JJ. Cell-type specific regulation and Bcl-2 expression by mood stabilizer drugs. Eur Neuropsychopharm. 2004;14:143-50.
6. Donovan M, Cotter TG. Control of mitochondrial integrity by Bcl-2 family members and caspase-independent cell death. Biochim Biophys Acta. 2004;1644:133-47.
7. Eilat E, Mendlovic S, Doron A, Zakuth V, Spirer Z. Increased apoptosis in patients with major depression: a preliminary study. J Immunol. 1999;163:533-4.
8. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trials. Am J Psychiatry. 2004;161:217-22.
9. Gould TD, Chen G, Manji HK. Mood stabilizer psychopharmacology. Clin Neurosci Res. 2002;2:193-212.
10. Ghribi O, Herman MM, Spaulding NK, Savory J. Lithium inhibits aluminum-induced apoptosis in rabbit hippocampus, by preventing cytochrome c translocation, Bcl-2 decrease, Bax elevation and caspase-3 activation. J Neurochem. 2002; 82:137-45.
11. Krystal JH, Sanacora G, Blumberg H, et al.Glutamate and GABA systems as targets for novel antidepressant and moood-stabilizing treatments. Mol Psychiatry. 2002;7:S71-80.
12. WAF/Cip1 on apoptosis and sensitivity to cancer chemotherapy. Drug Resist Updates. 2003;6:183-95.
13. Lowry DH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-75.
14. Lu R, Song L, Jope RS. Lithium attenuates p53 level in human neuroblastoma SH-SY5Y cells. Neuroreport. 1999;10:1123-5.
15. Mennerick S, Zorumski. CF. Glial contributions to excitatory neurotransmission in cultured hippocampal cells. Nature. 1994;368:59-62.
16. Mickisch G, Fajta S, Keilhauer G, Schlick E, Tschada R, Alken P. Chemosensitivity testing of primary renal cell carcinoma by tetrazolium-based microculture assy (MTT). Urol Res.1990;18:131-6.
17. Moghaddam B. Stress activation of glutamate neurotransmission in the prefrontal cortex: implications for dopamine-associated psychiatric disorders (Review). Biol Psychiatry. 2002;51:775-87.
18. +. Eur J Biochem. 1999;266:886-91.
19. Mora A, Sabio G, Alonso JC, Soler G, Centeno F. Different dependence of lithium and valproate on PI3K/PKB pathway. Bipolar Disord. 2002;4:195-200.
20. Nonaka S, Katsube N, Chuang DM. Lithium protects rat cerebellar cells against apoptosis induced by anticonvulsants, phenytoin and carbamazepine. J Pharmacol Exp Ther. 1998;286:539-47.
21. O'Connor DS, Grossman D, Plescia J, et al. Regulation of apoptosis at cell division by p34(cdc2) phosphorylation of survivin. Proc Natl Acad Sci USA. 2000;97:13103-7.
22. Osmak M, Vrhovec I, Skrk J. Cisplatin resistant glioblastoma cells have increased concentrations of urokinase plasminogen activator and plasminogen activator inhibitor type 1. J Neuro-Oncol. 1999;42:95-102.
23. Pfrieger FW, Barres BA. Synaptic efficacy enhanced by glial cells in vitro. Science. 1997;277:1684-7.
24. Salvesen GS, Duckett CS. IAP proteins: blocking the road to death's door. Nat Rev Mol Cell Biol. 2002;3:28-37.
25. Shi YG. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 2002;9:459-70.
26. Shin S, Sung BJ, Cho YS, et al. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7. Biochemistry. 2001;40:1117-23.
27. Skoufias DA, Mollinari C, Lacroix FB, Margolis RL. Human survivin is a kinetochore-associated passenger protein. J Cell Biol. 2000;151:1575-81.
28. Tapiero H, Mathe G, Couvreur P, Tew KD. Glutamine and glutamate. Biomed Pharmacother. 2002;56:446-57.
29. Tsacopoulos M, Magistretti PJ. Metabolic coupling between glia and neurons. J Neurosci. 1996;16:877-85.
30. Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol. 2003;195:158-67.
31. Verkhrastky A, Orkand RK, Kettenmann H. Glial calcium: homeostasis and signaling function. Physiol Rev. 1998;78:99-141.
32. Wada A, Yokoo H, Yanagita T, Kobayashi H. Lithium: potential therapeutics against acute brain injuries and chronic neurodegenerative diseases (Review). J Pharmacol Sci. 2005;99:307-21.
33. Yuan JY, Yanker BA. Apoptosis in the nervous system. Nature. 2000;407:802-9.
34. Yuan XP, Gould TD, Gray NA, et al. Nerotrophic signaling cascades are major long-term targets for lithium: clinical implications (Review). Clin Neurosci Res. 2004;4:137-53.